Q&A: Temperature Control & Logistics

16 January 2020 | 10:31 am
Temperature Control & Logistics is a hands on conference taking place the 27-30 January 2020 in Düsseldorf to discuss everything logistics, supply chain and temperature controlled for the pharmaceutical industry. Nordic Life Science asked Emily Shirrefs, Conference producer of Temperature Control & Logistics, about the upcoming event. What have been the outcomes from your previous […]

Positive results about Xinnate’s wound gel published

16 January 2020 | 9:30 am
Xinnate Board
On January 1st a scientific article on the mechanisms and the effect of the company’s wound gel was published in Science Translational Medicine. Swedish startup Xinnate has developed a wound gel in collaboration with a research group at the University of Lund. In animal studies the gel has been shown to work better than conventional […]

New study shows Sigrid’s medical device prevents weight gain

16 January 2020 | 8:46 am
Sana Alajmovic
Sigrid Therapeutics has announced the publication of a study in mice in the journal Nanomedicine demonstrating the enzyme-blocking effects of mesoporous silica particles (MSPs) introduced to the gut and the resulting effect on food efficiency and metabolic risk factors. “These results are very exciting and open up for new possibilities of SiPore15 to be used […]

Microsoft and MSD in strategic partnership for Nordic and Baltic life science

16 January 2020 | 8:39 am
Jakob Tellgren
The two companies have agreed on a partnership for the Nordic and Baltic markets with the aim to support healthcare. One possible field of cooperation is the use of cutting-edge technique, such as artificial intelligence, to support early diagnosis for i.a. lung cancer, they state. “The Nordic and Baltic states are at the forefront of […]

She is the new CEO of Novozymes

16 January 2020 | 8:19 am
Ester Baiget
On 1 February 2020, Ester Baiget will take up the position as President & CEO of Novozymes. Baiget joins from a position as Business President for Dow’s Industrial Solutions and is a member of the executive leadership team. She is an experienced international leader with a strong track-record, states the company. She will succeed Peder […]

Novo Nordisk collaborates with University of Virginia Center for Diabetes Technology

16 January 2020 | 8:08 am
Novo Nordisk Headquarter Denmark
University of Virginia (UVA) Center for Diabetes Technology and Novo Nordisk have announced that they have entered into a five-year research collaboration. The two collaborators will work together on the development of virtual environments focused on modelling of patients with type 2 diabetes. A ‘virtual innovation lab’ The goal of the collaboration is to enable […]

Single Technologies raises SEK 15 million

15 January 2020 | 8:52 am
Single Technologies raises SEK 15 million
Single Technologies has announced the completion of an oversubscribed SEK 15 million convertible bond issue. JOVB Holding acted as lead investor and the funds will be used to accelerate development of the company’s DNA sequencing platform Theta. The company was founded in 2014 following several years of research in single molecule imaging and biotechnology applications […]

Boosting women to the top

15 January 2020 | 8:19 am
Barbro Ehnbom
Barbro Ehnbom has successfully promoted women in their careers, not least within life sciences, and she is herself a living example of the changes she has pushed for.

Getinge acquires Applikon Biotechnology

14 January 2020 | 9:35 am
Mattias Perjos
Just before Christmas Getinge announced an agreement to acquire 100% of the shares in Applikon Biotechnology. Applikon Biotechnology is a company in the area of advanced bioreactor systems for biopharmaceutical production and research, with an annual net sales of approximately SEK 450 million. “Applikon Biotechnology has a strong portfolio of world class bioreactor solutions which […]

AstraZeneca closes its Phase III STRENGTH trial for Epanova

14 January 2020 | 7:27 am
AstraZeneca closes its Phase III STRENGTH trial for Epanova
Following the recommendation from an independent Data Monitoring Committee, AstraZeneca has decided to close the Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) due to its low likelihood of demonstrating a benefit to patients with mixed dyslipidaemia (MDL) who are at increased risk of cardiovascular (CV) disease. STRENGTH is a large-scale, global CV outcomes trial designed […]